Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,358 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,358 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05490043 | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell… | Phase 1 | terminated | Aug 5, 2022 | Antengene (Hangzhou) Biologics Co., Ltd. | The sponsor has decided to adjust the development strategy of the investigational drug in this… | Sponsor / business decision |
| NCT03376477 | Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in… | Phase 2 | terminated | Dec 18, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | loss of funding | Funding |
| NCT05883449 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL(LuminICE-203) | Phase 2 | terminated | Jun 1, 2023 | Affimed GmbH | Due to sponsor decision | Sponsor / business decision |
| NCT03015792 | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 1 | terminated | Jan 10, 2017 | Mayo Clinic | Drug company decided to not fund the phase 2 portion | Funding |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Phase 1 | terminated | Sep 14, 2016 | Novartis Pharmaceuticals | The decision of early termination was made due to business reasons, and was not based on any safety… | Safety / toxicity |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed… | Phase 1 / Phase 2 | terminated | Sep 2, 2021 | M.D. Anderson Cancer Center | The study was terminated early due to slow enrollment. | Enrollment / accrual |
| NCT04433182 | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large… | Phase 2 | terminated | Jun 16, 2020 | Fondazione Italiana Linfomi - ETS | low enrollment rate | Enrollment / accrual |
| NCT05655546 | ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised… | N/A | terminated | Dec 19, 2022 | Scripps Translational Science Institute | On May 13, 2024, the FDA released a communication that Cue Health tests should no longer be used. | Other (stated, no rule matched) |
| NCT06005649 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | withdrawn | Aug 22, 2023 | Juventas Cell Therapy Ltd. | Sponsor changed product development plan | Other (stated, no rule matched) |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | Phase 2 | terminated | Mar 5, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT06588660 | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Sep 19, 2024 | University of Washington | Study terminated due to end of funding. | Funding |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+…(NAVAL-1) | Phase 2 | terminated | Aug 18, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04493411 | Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using… | N/A | terminated | Jul 30, 2020 | University of Texas Southwestern Medical Center | Funding expired before enrollment goal could be reached. | Enrollment / accrual |
| NCT03401853 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or… | Phase 2 | terminated | Jan 17, 2018 | University of Washington | Study terminated to end of funding. | Funding |
| NCT04125290 | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(PROXY) | — | terminated | Oct 14, 2019 | AstraZeneca | Study stopped due to lack of recruitment. | Enrollment / accrual |
| NCT05879458 | Ritlecitinib in CTCL | Phase 2 | terminated | May 30, 2023 | Icahn School of Medicine at Mount Sinai | No significant improvement in disease as graded by our assessments. | Other (stated, no rule matched) |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment…(ALEXANDER) | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Autolus Limited | After reviewing the data and taking into consideration the available treatment landscape in r/r… | Other (stated, no rule matched) |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd…(BIOSELECT) | Phase 1 / Phase 2 | withdrawn | Sep 14, 2022 | AHS Cancer Control Alberta | Contractual Issues | Other (stated, no rule matched) |
| NCT05442580 | CART-38 in Adult AML and MM Patients | Phase 1 | terminated | Jul 5, 2022 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05121103 | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative… | Phase 1 | terminated | Nov 16, 2021 | Epizyme, Inc. | Strategic business decision | Sponsor / business decision |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | Phase 1 | terminated | Feb 3, 2021 | Adicet Therapeutics | Terminated - Halted Prematurely | Other (stated, no rule matched) |
| NCT05027594 | Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Aug 30, 2021 | Nerviano Medical Sciences | The decision is not based on emerging safety or efficacy concerns but on strategic reasons related… | Safety / toxicity |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel… | N/A | withdrawn | Nov 3, 2021 | Case Comprehensive Cancer Center | Study closed prior to enrollment of first participant | Enrollment / accrual |
| NCT04986865 | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell…(PROBE) | Phase 1 | terminated | Aug 3, 2021 | Antengene Biologics Limited | It is due to the recent changes in the competitor landscape and strategic consideration | Sponsor / business decision |
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With…(SWATCH) | Phase 1 / Phase 2 | terminated | Mar 4, 2022 | Antengene Corporation | The adjustment of the sponsor's research and development strategy | Sponsor / business decision |
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression…(BOSS) | Phase 2 | withdrawn | Feb 21, 2025 | AstraZeneca | AstraZeneca has made the decision to cancel the trial. | Other (stated, no rule matched) |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute… | Early Phase 1 | terminated | Jul 26, 2019 | Institute of Hematology & Blood Diseases Hospital, China | Due to adjustments in the company's strategy, the research and development of this project has been… | Sponsor / business decision |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | Phase 1 / Phase 2 | terminated | May 9, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Poor accrual | Enrollment / accrual |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | terminated | Dec 6, 2019 | University of Miami | Investigator Decision | Investigator |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | Gilead Sciences | Study terminated early due to the magrolimab program discontinuation. | Other (stated, no rule matched) |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT05788289 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | Phase 2 | terminated | Mar 28, 2023 | Memorial Sloan Kettering Cancer Center | Slow accrual rate | Enrollment / accrual |
| NCT02811679 | A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin… | Phase 2 | terminated | Jun 23, 2016 | Massachusetts General Hospital | Study closed early due to slow accrual | Enrollment / accrual |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed,… | Phase 1 | terminated | May 19, 2021 | Mayo Clinic | Low/slow accrual - did not proceed to Phase 2 | Enrollment / accrual |
| NCT00626444 | Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) | Phase 2 | terminated | Feb 29, 2008 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04570631 | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in… | Phase 1 | terminated | Sep 30, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and… | — | withdrawn | Jan 5, 2021 | Memorial Sloan Kettering Cancer Center | Lack of potential participants given the other treatment options currently available to people | Other (stated, no rule matched) |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Jun 21, 2019 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial… | Early Phase 1 | terminated | Nov 17, 2016 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | — | terminated | Jul 6, 2016 | AIDS Malignancy Consortium | Poor accrual | Enrollment / accrual |
| NCT05833737 | Corneal Findings in Patients Treated With Belantamab Mafodotin | — | terminated | Apr 27, 2023 | Medical University of Vienna | Study medication market withdrawal by FDA. | Other (stated, no rule matched) |
| NCT06290622 | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Phase 1 | withdrawn | Mar 4, 2024 | University of Alabama at Birmingham | Investigator request to no longer pursue this study. Lack of support from drug company. This trial… | Investigator |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in… | Phase 1 | withdrawn | Sep 14, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04217317 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell… | Phase 2 | terminated | Jan 3, 2020 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | May 19, 2021 | Gilead Sciences | This study was terminated early due to the Sponsor's decision to discontinue development of the… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 29, 2025source: clinicaltrials